The compelling need for a cardiology and oncology partnership and the birth of the international cardioncology society

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 88-93

  Lenihan, Daniel J ^a   Cardinale, Daniela ^b   Cipolla, Carlo M ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti angiogenesis; Cardiology and oncology; Cardiotoxicity; Chemotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; HEART ENZYME; HYPERTENSIVE FACTOR; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; AMYLOIDOSIS; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CARDIOLOGY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA BASE; DRUG TREATMENT FAILURE; ECHOCARDIOGRAPHY; HEART ASSIST DEVICE; HEART DISEASE; HEART FAILURE; HEART FUNCTION TEST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL CARE; MEDICAL PRACTICE; MEDICAL SOCIETY; METASTASIS POTENTIAL; ONCOLOGY; PERICARDIAL EFFUSION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; RISK ASSESSMENT; STANDARDIZATION; STEM CELL TRANSPLANTATION; STOMACH LYMPHOMA; CHEMICALLY INDUCED; COMPLICATION; COOPERATION; DRUG INTERACTION; HEART DISEASES; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; NEOPLASMS; PATIENT CARE; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARDIOLOGY; CARDIOVASCULAR AGENTS; COOPERATIVE BEHAVIOR; DRUG INTERACTIONS; HEART DISEASES; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 77955900436     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.06.002     Document Type: Article

References (23)

1. Cardinale D. A new frontier: cardio-oncology. Cardiologia 1996, 41:887-891.
2. Driver J.A., Djousse L., Logroscino G., et al. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ 2008, a2467:337.
3. Sanz J., Moreno P.R., Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2007, 49:1740-1749.
4. Vaklavas C., Lenihan D., Kurzrock R., et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 2010, 15:130-141.
5. Albini A., Pennesi G., Donatelli F., et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
6. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
7. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
8. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
9. Telli M.L., Witteles R.M., Fisher G.A., et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19:1613-1618.
10. van Royen N., Piek J.J., Schaper W., et al. A critical review of clinical arteriogenesis research. J Am Coll Cardiol 2009, 55:17-25.
11. Mathur A., Martin J.F. Stem cells and repair of the heart. Lancet 2004, 364:183-192.
12. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
13. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
14. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
15. Gianni L., Herman E.H., Lipshultz S.E., et al. Anthracycline cardiotoxicity: from bench to bedside. Journal of Clinical Oncology 2008, 26:3777-3784.
16. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
17. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JACC 2010, 55:213-220.
18. Maitland M.L., Bakris G.L., Black H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010, 102:596-604.
19. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
20. Chandra S., Lenihan D.J., Wei W., et al. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J 2009, 36:205-213.
21. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 2008, 26:1201-1203.
22. Bird B.R., Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14:14-24.
23. Goldsmith Y.B., Liu J., Chou J., et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol 2009, 104:990-994.